Literature DB >> 2789256

IL-6/IFN-beta 2 in synovial effusions of patients with rheumatoid arthritis and other arthritides. Identification of several isoforms and studies of cellular sources.

N Bhardwaj1, U Santhanam, L L Lau, S B Tatter, J Ghrayeb, M Rivelis, R M Steinman, P B Sehgal, L T May.   

Abstract

We have looked for IL-6, a cytokine that has immunomodulating and inflammation-associated activities, in joint exudates (fluid and mononuclear cells) from patients with rheumatoid arthritis and other arthritides using both biologic and biochemical assays. IL-6 was assessed by its ability to stimulate alpha 1-antichymotrypsin secretion from the human hepatoma cell line Hep3B clone 2, an activity which is blocked by an antiserum to Escherichia coli derived IL-6, and by the growth of the IL-6-dependent murine hybridoma 7TD1 cell line. IL-6 isoforms in synovial fluid were characterized by immunoaffinity chromatography followed by Western blotting. The presence of IL-1 in synovial fluids and its production by synovial fluid mononuclear cells was monitored by Western blotting and indirect immunofluorescence with polyclonal anti-IL-1 beta antisera. In an analysis of 30 effusions from 27 rheumatoid patients with acutely inflamed joints, abundant quantities of IL-6 (greater than 2 ng/ml) were detected in 23 by the alpha 1-antichymotrypsin bioassay. Several rheumatoid synovial fluids also had elevated IL-6 levels in the 7TD1 bioassay. Seven of nine nonrheumatoid effusions also contained high levels of IL-6 (greater than 2 ng/ml). No IL-1 (less than 0.25 ng/ml) could be detected by Western blotting in 10 rheumatoid effusions even though eight of these contained high levels of IL-6. The IL-6 activity could be neutralized with a rabbit antiserum to rIL-6. Multiple IL-6 isoforms (25, 30, 45 kDa) were present in two rheumatoid and one traumatic effusion studied. Fresh mononuclear cells isolated from various synovial effusions did not appear to make IL-6 constitutively, as no IL-6 could be detected in the media of cells cultured for 12 to 18 h after isolation. Similarly, there was no constitutive production of IL-1 by these cells. However, synovial fluid mononuclear cells could be induced to secrete both IL-6 and IL-1 after stimulation with LPS. The LPS-responsive cells were monocytes and not lymphocytes or dendritic cells. These findings suggest that IL-6 is involved in inflammatory joint disease. However, the primary cells synthesizing it may be located in the synovial lining instead of the joint exudate.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2789256

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  33 in total

1.  Effects of Allergina on the treatment of otitis media with effusions.

Authors:  Hyun-Ja Jeong; Seung-Heon Hong; Sung-Chul Kim; Eun-Jeong Park; Chul-Ho Jang; Kyung-Suk Kim; Hyung-Min Kim
Journal:  Inflammation       Date:  2002-04       Impact factor: 4.092

2.  Phenotypic analysis of functionally associated molecules on peripheral blood and synovial fluid monocytes from arthritis patients.

Authors:  S J Gadd; T Felzmann; O Majdic; D Maurer; P Petera; W J Chen; J Smolen; W Knapp
Journal:  Rheumatol Int       Date:  1992       Impact factor: 2.631

Review 3.  Production of inflammatory cytokines in the intestinal lamina propria.

Authors:  C Fiocchi
Journal:  Immunol Res       Date:  1991       Impact factor: 2.829

4.  Tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-6 expression in inflammatory bowel disease.

Authors:  C Stevens; G Walz; C Singaram; M L Lipman; B Zanker; A Muggia; D Antonioli; M A Peppercorn; T B Strom
Journal:  Dig Dis Sci       Date:  1992-06       Impact factor: 3.199

5.  Dual Inhibition of TNFR1 and IFNAR1 in Imiquimod-Induced Psoriasiform Skin Inflammation in Mice.

Authors:  Lynda Grine; Lien Dejager; Claude Libert; Roosmarijn E Vandenbroucke
Journal:  J Immunol       Date:  2015-04-24       Impact factor: 5.422

6.  Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity.

Authors:  R Madhok; A Crilly; J Watson; H A Capell
Journal:  Ann Rheum Dis       Date:  1993-03       Impact factor: 19.103

7.  Differential induction of tumor necrosis factor alpha in murine and human leukocytes by Mycoplasma arthritidis-derived superantigen.

Authors:  L Rink; W Nicklas; L Alvarez-Ossorio; M Koester; H Kirchner
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

8.  Differential effects of leflunomide and methotrexate on cytokine production in rheumatoid arthritis.

Authors:  M C Kraan; T J M Smeets; M J van Loon; F C Breedveld; B A C Dijkmans; P P Tak
Journal:  Ann Rheum Dis       Date:  2004-04-28       Impact factor: 19.103

Review 9.  Interleukin-6 in autoimmune disease. Role of IL-6 in physiology and pathology of the immune defense.

Authors:  L Graeve; M Baumann; P C Heinrich
Journal:  Clin Investig       Date:  1993-08

10.  Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab.

Authors:  Norihiro Nishimoto; Jun Hashimoto; Nobuyuki Miyasaka; Kazuhiko Yamamoto; Shinichi Kawai; Tsutomu Takeuchi; Norikazu Murata; Désirée van der Heijde; Tadamitsu Kishimoto
Journal:  Ann Rheum Dis       Date:  2007-05-07       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.